Mismatch Between Global Disease Burden In Youths And Research Devoted To Pediatric Patients
Although children are more likely than adults to suffer from many diseases, few clinical trials are being conducted to test drugs in pediatric patients, according to a study presented at the Pediatric Academic Societies (PAS) annual meeting in Boston.
Drug studies in children are important because children often respond differently to medications than adults. However, there is widespread concern about the lack of clinical evidence available to guide physicians in prescribing pharmaceuticals to children.
Florence Bourgeois, MD, MPH, assistant professor at Harvard Medical School, and her colleagues sought to measure how much research activity is devoted to conditions representing a high burden of pediatric disease. They identified all drug trials for the 10 highest burden conditions registered from 2006 to 2011 in ClinicalTrials.gov, a database of federally and privately supported clinical trials conducted around the world. These conditions included asthma, migraine headaches, schizophrenia, depression, diarrheal illness, lower respiratory infection, malaria, bipolar disorder and HIV/AIDS.
"We found that there is a large discrepancy between global disease burden in children and the amount of clinical trial research devoted to this population," Dr. Bourgeois said.
While nearly 60 percent of the disease burden for high-priority conditions is borne by children, only 12 percent of clinical drug trials are pediatric trials. This discrepancy was greatest for conditions prevalent in middle- and low-income countries.
Funding sources may play a large part in the amount of research devoted to pediatric populations, Dr. Bourgeois said. "We found that 58.6 percent of pediatric drug trials were conducted without any industry funding, relying solely on nonprofit organizations. In contrast, the majority of adult drug trials (64.7 percent) received industry funding."
Additional programs and incentives are needed to increase the number of drugs tested in children by pharmaceutical companies and noncommercial entities, Dr. Bourgeois said. "It is critical that drugs are studied that are most likely to benefit children, particularly children in developing countries who appear to be most neglected in the current research portfolio."
Researchers also found differences between the designs of pediatric and adult trials. For example, studies conducted in adults were more likely to focus on safety outcomes and to be multicenter trials.
"As has long been suspected, children suffering from both acute and chronic diseases are not well-served by the current drug development and approval processes," said Kenneth Mandl, MD, MPH, senior author of the study and associate professor at Harvard Medical School.
Added: 05 мая 2012
Added: 05 мая 2012
Last relative articles:
- Researchers Urge More Patient-Centered Care For African-American Breast Cancer Survivors
- Flutemetamol For Alzheimer's - Phase 3 Results Released
- Warning Patients Of Impending Heart Attack Via Implantable Medical Device
- Significant Improvement In Disability Scores With Alemtuzumab
- Cimzia Trial Shows Promise For Axial Spondyloarthritis And Ankylosing Spondylitis
- New Evidence Is Helping Explain Additional Health Benefits Of Aspirin
- Ultra-Long-Acting Insulin Degludec, Two Phase 3 Studies Published
- Health Research Strategy Not Present In Many Nations
- Oral Cancer Detection Could Dramatically Increase With Saliva Test
- Interim Results Of Neuralstem ALS Stem Cell Trial
- Key Mechanism Behind Lymphoma Targeted By New Compound
- First Targeted Nanomedicine To Enter Human Clinical Studies
- Researchers Prepare Clinical Trial That Will Use Fat-Enclosed Nanoparticles To Accurately Irradiate Brain Tumors
- Clinicians May Be Mislead Over Effectiveness Of Newer Anti-Psychotic Drugs
- Reversal Of Fragile X Syndrome In Mouse Model